June 3, 2015 | Israeli pharmaceutical company Teva Pharmaceutical Industries announced the launch of a generic ADHD treatment, the equivalent of the INTUNIV drug. The generic version of INTUNIV will be launched in the United States in 1, 2, 3 and 4 milligram doses. The INTUNIV drug is made up of a chemical called Guanfacine that is a non-stimulant treatment for ADHD.
Related posts
US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Israeli Startups Raise $1.6B in Q3, Indicating Stabilization - Report
September 27, 2023
Global Chip Maker Buying Renewable Energy From Israeli Firm
September 27, 2023
VC Fund Raises $480M For Cybersecurity Investment
September 26, 2023
Facebook comments